Fingolimod for relapsing multiple sclerosis: An update

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 7, 2010, Pages 1183-1196

  Horga, Alejandro ^a   Castilló, Joaqun ^a   Montalban, Xavier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Fingolimod; FTY720; Multiple sclerosis; Sphingosine 1 phosphate; Sphingosine 1 phosphate receptors

Indexed keywords

ATROPINE; BETA1A INTERFERON; CORTICOSTEROID; CYCLOSPORIN; FINGOLIMOD; GADOLINIUM; PLACEBO;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC ENCEPHALOMYELITIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATRIOVENTRICULAR BLOCK; B LYMPHOCYTE; BRADYCARDIA; BREAST CANCER; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DIZZINESS; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; HEART PALPITATION; HERPES SIMPLEX ENCEPHALITIS; HERPES ZOSTER; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LYMPHOCYTOPENIA; LYMPHOID ORGAN; MEAN ARTERIAL PRESSURE; MULTIPLE SCLEROSIS; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; RELAPSE; RESPIRATORY TRACT INFECTION; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; SKIN TUMOR; T LYMPHOCYTE; THORAX PAIN;

ADMINISTRATION, ORAL; ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

EID: 77951275983     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003769866     Document Type: Review

References (113)

1. Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006;13:700-722 (Pubitemid 44143944)
2. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-1517
3. Galetta SL, Markowitz C. US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles. CNS Drugs 2005;19:239-252 (Pubitemid 40460663)
4. Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007;356:2622-2629
5. Huwiler A, Pfeilschifter J. New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. Biochem Pharmacol 2008;75:1893-1900
6. Marsolais D, Rosen H. Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nat Rev Drug Discov 2009;8:297-307
7. Salvadori M, Budde K, Charpentier B, et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant 2006;6:2912-2921
8. Tedesco-Silva H, Pescovitz MD, Cibrik D, et al. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation 2006;82:1689-1697 (Pubitemid 46035653)
9. Horga A, Montalban X. FTY720 (fingolimod) for relapsing multiple sclerosis. Expert Rev Neurother 2008;8:699-714 (Pubitemid 351656821)
10. Le Stunff H, Milstien S, Spiegel S. Generation and metabolism of bioactive sphingosine-1-phosphate. J Cell Biochem 2004;92:882-899 (Pubitemid 44264239)
11. Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem 2004;92:913-922 (Pubitemid 44264241)
12. Jaillard C, Harrison S, Stankoff B, et al. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci 2005;25:1459-1469 (Pubitemid 40250722)
13. Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol 2005;5:560-570 (Pubitemid 40961333)
14. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007;115:84-105 (Pubitemid 46990553)
15. McVerry BJ, Garcia JG. Endothelial cell barrier regulation by sphingosine 1-phosphate. J Cell Biochem 2004;92:1075-1085 (Pubitemid 44264219)
16. Peters SL, Alewijnse AE. Sphingosine-1-phosphate signaling in the cardiovascular system. Curr Opin Pharmacol 2007;7:186-192
17. Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 2007;8:1295-1301
18. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296:346-349 (Pubitemid 34303689)
19. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002;277:21453-21457 (Pubitemid 34952287)
20. Liu CH, Thangada S, Lee MJ, et al. Ligand-induced trafficking of the sphingosine-1-phosphate receptor EDG-1. Mol Biol Cell 1999;10:1179-1190 (Pubitemid 29193739)
21. Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. Faseb J 2004;18:551-553
22. Oo ML, Thangada S, Wu MT, et al. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 2007;282:9082-9089 (Pubitemid 47093504)
23. Mullershausen F, Zecri F, Cetin C, et al. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol 2009;5:428-434
24. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355-360 (Pubitemid 38133663)
25. Allende ML, Dreier JL, Mandala S, Proia RL. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem 2004;279:15396-15401 (Pubitemid 38618938)
26. Schwab SR, Pereira JP, Matloubian M, et al. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 2005;309:1735-1739 (Pubitemid 41285945)
27. von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000;343:1020-1034
28. Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007;316:295-298 (Pubitemid 46633109)
29. Lo CG, Xu Y, Proia RL, Cyster JG. Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. J Exp Med 2005;201:291-301 (Pubitemid 40189438)
30. Chiba K, Yanagawa Y, Masubuchi Y, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998;160:5037-5044 (Pubitemid 28215340)
31. Yanagawa Y, Masubuchi Y, Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer's patches by FTY720-induced lymphocyte homing. Immunology 1998;95:591-594 (Pubitemid 28559152)
32. Yanagawa Y, Sugahara K, Kataoka H, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J Immunol 1998;160:5493-5499 (Pubitemid 28267841)
33. Hwang MW, Matsumori A, Furukawa Y, et al. FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation. Circulation 1999;100:1322-1329 (Pubitemid 29440126)
34. Kurose S, Ikeda E, Tokiwa M, et al. Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats. Exp Eye Res 2000;70:7-15 (Pubitemid 30046870)
35. Fujino M, Funeshima N, Kitazawa Y, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 2003;305:70-77 (Pubitemid 36378136)
36. Kataoka H, Sugahara K, Shimano K, et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2005;2:439-448
37. Xie JH, Nomura N, Koprak SL, et al. Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells. J Immunol 2003;170:3662-3670 (Pubitemid 36359236)
38. Drennan MB, Elewaut D, Hogquist KA. Thymic emigration: sphingosine-1-phosphate receptor-1- dependent models and beyond. Eur J Immunol 2009;39:925-930
39. Lan YY, De Creus A, Colvin BL, et al. The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. Am J Transplant 2005;5:2649-2659 (Pubitemid 43920058)
40. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745-763 (Pubitemid 38680440)
41. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008;71:1261-1267
42. Brinkmann V, Pinschewer D, Chiba K, Feng L. FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol Sci 2000;21:49-52 (Pubitemid 30100338)
43. Pinschewer DD, Ochsenbein AF, Odermatt B, et al. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000;164:5761-5770 (Pubitemid 30389819)
44. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004;4:1019-1025 (Pubitemid 38868590)
45. McFarland HF. The B cell-old player, new position on the team. N Engl J Med 2008;358:664-665
46. Lopez-Diego RS, Weiner HL. Novel therapeutic strategies for multiple sclerosis-a multifaceted adversary. Nat Rev Drug Discov 2008;7:909-925
47. Dev KK, Mullershausen F, Mattes H, et al. Brain sphingosine-1-phosphate receptors: Implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 2008;117:77-93 (Pubitemid 350192672)
48. Pebay A, Toutant M, Premont J, et al. Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades. Eur J Neurosci 2001;13:2067-2076 (Pubitemid 32664301)
49. Mullershausen F, Craveiro LM, Shin Y, et al. Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J Neurochem 2007;102:1151-1161 (Pubitemid 47174238)
50. Miron VE, Jung CG, Kim HJ, et al. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008;63:61-71
51. MacLennan AJ, Devlin BK, Marks L, et al. Antisense studies in PC12 cells suggest a role for H218, a sphingosine 1-phosphate receptor, in growth-factor-induced cell-cell interaction and neurite outgrowth. Dev Neurosci 2000;22:283-295
52. Sorensen SD, Nicole O, Peavy RD, et al. Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol Pharmacol 2003;64:1199-1209 (Pubitemid 37310753)
53. Yamagata K, Tagami M, Torii Y, et al. Sphingosine 1-phosphate induces the production of glial cell line-derived neurotrophic factor and cellular proliferation in astrocytes. Glia 2003;41:199-206 (Pubitemid 36262197)
54. Toman RE, Payne SG, Watterson KR, et al. Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension. J Cell Biol 2004;166:381-392
55. Harada J, Foley M, Moskowitz MA, Waeber C. Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J Neurochem 2004;88:1026-1039 (Pubitemid 38199325)
56. Saini HS, Coelho RP, Goparaju SK, et al. Novel role of sphingosine kinase 1 as a mediator of neurotrophin-3 action in oligodendrocyte progenitors. J Neurochem 2005;95:1298-1310
57. Rouach N, Pebay A, Meme W, et al. S1P inhibits gap junctions in astrocytes: involvement of G and Rho GTPase/ROCK. Eur J Neurosci 2006;23:1453-1464
58. Novgorodov AS, El-Alwani M, Bielawski J, et al. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. Faseb J 2007;21:1503-1514 (Pubitemid 46684852)
59. Miron VE, Schubart A, Antel JP. Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci 2008;274:13-17
60. Foster CA, Howard LM, Schweitzer A, et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 2007;323:469-475 (Pubitemid 350005125)
61. Coelho RP, Payne SG, Bittman R, et al. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 2007;323:626-635 (Pubitemid 350005137)
62. Miron VE, Hall JA, Kennedy TE, et al. Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod. Am J Pathol 2008;173:1143-1152
63. Jung CG, Kim HJ, Miron VE, et al. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia 2007;55:1656-1667
64. Deogracias R, Klein C, Matsumoto T, et al. Expression of brain-derived neurotrophic factor is regulated by fingolimod (FTY720) in cultured neurons. Multiple Sclerosis 2008;14:S243 [P728]
65. Choi JW, Herr D, Lee CW, et al. S1P1 receptor signaling on cells of astrocytic lineages in experimental autoimmune encephalomyelitis: a role in disease progression and the efficacy of fingolimod (FTY720). Multiple Sclerosis 2008;14:S37 [P29]
66. Choi JW, Herr D, Kennedy G, Chun J. Astrocytic sphingosine-1-phosphate (S1P) receptor subtype 1 signalling influences levels of S1P and cytokines during experimental autoimmune encephalomyelitis and fingolimod (FTY720) intervention. Multiple Sclerosis 2009;15:S58 [P227]
67. Budde K, Schmouder RL, Brunkhorst R, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002;13:1073-1083 (Pubitemid 34274106)
68. Budde K, Schmouder RL, Nashan B, et al. Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am J Transplant 2003;3:846-854 (Pubitemid 36827906)
69. Kovarik JM, Schmouder R, Barilla D, et al. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol 2004;57:586-591 (Pubitemid 38582178)
70. Kahan BD, Karlix JL, Ferguson RM, et al. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplantation 2003;76:1079-1084
71. Skerjanec A, Tedesco H, Neumayer HH, et al. FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship. J Clin Pharmacol 2005;45:1268-1278 (Pubitemid 41513050)
72. Kovarik JM, Schmouder R, Barilla D, et al. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol 2004;44:532-537 (Pubitemid 38509722)
73. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-1140 (Pubitemid 44394919)
74. O'Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009;72:73-79
75. Comi G, O'Connor P, Montalban X, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2010;16:197-207
76. Cohen JA, Barkhof F, Comi G, et al. Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. N Engl J Med 2010;362:402-415
77. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
78. Mazurais D, Robert P, Gout B, et al. Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem 2002;50:661-670 (Pubitemid 34437559)
79. Gergely P, Wallstrom E, Nuesslein-Hildesheim B, et al. Phase I study with the selective S1P1/S1P5 receptor modulator BAF312 indicates that S1P1 rather than S1P3 mediates transient heart rate reduction in humans. Multiple Sclerosis 2009;15:S125 [P437]
80. Koyrakh L, Roman MI, Brinkmann V, Wickman K. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant 2005;5:529-536 (Pubitemid 40313344)
81. Coussin F, Scott RH, Wise A, Nixon GF. Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction. Circ Res 2002;91:151-157
82. Tolle M, Levkau B, Keul P, et al. Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. Circ Res 2005;96:913-920 (Pubitemid 40604976)
83. Pfaff M, Powaga N, Akinci S, et al. Activation of the SPHK/S1P signalling pathway is coupled to muscarinic receptor-dependent regulation of peripheral airways. Respir Res 2005;6:48 (Pubitemid 41363575)
84. Kovarik JM, Hartmann S, Bartlett M, et al. Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects. Biopharm Drug Dispos 2007;28:97-104 (Pubitemid 46455770)
85. Paugh SW, Payne SG, Barbour SE, et al. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 2003;554:189-193 (Pubitemid 37324838)
86. Kharel Y, Lee S, Snyder AH, et al. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J Biol Chem 2005;280:36865-36872 (Pubitemid 41587768)
87. Zemann B, Kinzel B, Muller M, et al. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 2006;107:1454-1458 (Pubitemid 43242381)
88. Kovarik JM, Schmouder RL, Slade AJ. Overview of FTY720 clinical pharmacokinetics and pharmacology. Ther Drug Monit 2004;26:585-587 (Pubitemid 39579137)
89. Kovarik JM, Schmouder RL, Hartmann S, et al. Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function. J Clin Pharmacol 2006;46:149-156 (Pubitemid 43146445)
90. Kovarik JM, Schmouder RL, Serra D, et al. FTY720 pharmacokinetics in mild to moderate hepatic impairment. J Clin Pharmacol 2005;45:446-452 (Pubitemid 40490417)
91. Clemens JJ, Davis MD, Lynch KR, Macdonald TL. Synthesis of para-alkyl aryl amide analogues of sphingosine-1-phosphate: discovery of potent S1P receptor agonists. Bioorg Med. Chem Lett 2003;13:3401-3404
92. Meno-Tetang GM, Li H, Mis S, et al. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4- octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos 2006;34:1480-1487 (Pubitemid 44285388)
93. Billich A, Bornancin F, Devay P, et al. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 2003;278:47408-47415 (Pubitemid 37523181)
94. Park SI, Felipe CR, Machado PG, et al. Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. Braz J Med Biol Res 2005;38:683-694 (Pubitemid 40867507)
95. Zimmerlin AG, Patten CJ. Role of CYP4F in the metabolic clearance of FTY720: prediction of low drug to drug interaction potential. Transplantation 2000;69:S191
96. Kovarik JM, Dole K, Riviere GJ, et al. Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition. J Clin Pharmacol 2009;49:212-218
97. Kahan BD. Update on pharmacokinetic/ pharmacodynamic studies with FTY720 and sirolimus. Ther Drug Monit 2002;24:47-52
98. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002;360:1155-1162
99. Kovarik JM, Hsu CH, Skerjanec A, et al. FTY720 disposition is not affected by demographic or clinical factors in de novo kidney transplant patients. Am J Transplant 2003;5:S332[705]
100. Kovarik JM, Slade A, Voss B, et al. Ethnic sensitivity study of fingolimod in white and Asian subjects. Int J Clin Pharmacol Ther 2007;45:98-109 (Pubitemid 46344141)
101. Sensken SC, Bode C, Graler MH. Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy. J Pharmacol Exp Ther 2009;328:963-969
102. Rausch M, Hiestand P, Foster CA, et al. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 2004;20:16-24 (Pubitemid 38857512)
103. Balatoni B, Storch MK, Swoboda EM, et al. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 2007;74:307-316 (Pubitemid 47368881)
104. Foster CA, Mechtcheriakova D, Storch MK, et al. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol 2009;19:254-266
105. Papadopoulos D, Rundle J, Patel R, et al. FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses. J Neurosci Res 2010;88:346-359
106. Webb M, Tham CS, Lin FF, et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 2004;153:108-121 (Pubitemid 38950933)
107. Tedesco-Silva H, Mourad G, Kahan BD, et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase IIA study in de novo renal transplantation. Transplantation 2005;79:1553-1560 (Pubitemid 40847587)
108. Schmouder R, Serra D, Wang Y, et al. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol 2006;46:895-904 (Pubitemid 44050826)
109. Mulgaonkar S, Tedesco H, Oppenheimer F, et al. FTY720/ cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study. Am J Transplant 2006;6:1848-1857 (Pubitemid 44024956)
110. Oppenheimer F, Mulgaonkar S, Ferguson R, et al. Impact of long-term therapy with FTY720 or mycophenolate mofetil on cardiac conduction and rhythm in stable adult renal transplant patients. Transplantation 2007;83:645-648 (Pubitemid 46440256)
111. Kovarik JM, Slade A, Riviere GJ, et al. The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects. Br J Clin Pharmacol 2008;66:199-206 (Pubitemid 351991450)
112. Stott VL, Hurrell MA, Anderson TJ. Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Intern Med J 2005;35:83-90 (Pubitemid 40343439)
113. Leypoldt F, Munchau A, Moeller F, et al. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology 2009;72:1022-1024